Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Trial Profile

Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Avelumab (Primary) ; PF 4518600 (Primary) ; Utomilumab (Primary) ; Cisplatin
  • Indications Cervical cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 Sep 2022 to 1 Aug 2022.
    • 10 Aug 2017 Planned primary completion date changed from 1 Sep 2022 to 1 Aug 2022.
    • 10 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top